Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
ST

NASDAQ · STOK

Stoke Therapeutics, Inc.

Healthcare · Biotechnology

$26.29

Down-$0.06 (-0.23%)

Updated Nov 1, 2026, 11:28 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.89B
P/E ratio
47.82
Dividend yield
0.00%
52-week range
$22.05 – $40.22
Volume
1.86M
Avg. volume
1.2M

Price performance · STOK

STOK price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

STOK closed at $26.29 after 20 trading sessions, up 3.83% for the selected period.

Last close
$26.29
Period change
+3.83%
Period low
$22.50
Period high
$26.61
Daily close
View OHLC price history
STOK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$26.04$26.715$25.76$26.291.86M
Oct 29, 2026$26.39$27.00$26.03$26.351.88M
Oct 28, 2026$25.68$26.52$25.54$26.41781.36K
Oct 27, 2026$25.44$26.35$25.215$26.131.33M
Oct 26, 2026$25.22$25.52$24.52$25.462.08M
Oct 23, 2026$25.53$25.8322$24.80$25.042.16M
Oct 22, 2026$25.88$26.72$25.64$25.701.35M
Oct 21, 2026$26.83$27.22$25.31$25.682.26M
Oct 20, 2026$24.95$27.22$24.84$26.612.46M
Oct 19, 2026$24.49$25.02$24.13$24.82711.01K
Oct 16, 2026$24.56$24.61$23.635$24.17880.15K
Oct 15, 2026$23.54$24.62$23.45$24.61818.18K
Oct 14, 2026$22.43$23.355$22.05$23.261.09M
Oct 13, 2026$24.05$24.06$22.30$22.50618.02K
Oct 12, 2026$24.65$24.67$24.10$24.15372.99K
Oct 9, 2026$23.98$25.20$23.79$24.74918.96K
Oct 8, 2026$24.04$24.29$23.645$23.95692.28K
Oct 7, 2026$24.13$24.70$23.95$24.29637.1K
Oct 6, 2026$25.58$25.725$23.00$24.371.17M
Oct 5, 2026$25.82$26.31$24.835$25.32928.39K

Latest STOK news

The latest Smart Investors Daily articles mentioning STOK.

Stock researchCompany · Overview

STOK research

Overview

Company profile and research snapshot.

Company profile

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$30.33
Implied upside
—
Analysts
16
STOK recent ratings
DateFirmRatingTarget
Aug 21, 2026JP MorganOverweight—
Aug 4, 2026GuggenheimBuy—
Aug 4, 2026WedbushOutperform—
Aug 4, 2026Chardan CapitalBuy—
Aug 4, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

BEDFORD, Mass., October 22, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, October 29, 2026, at 4:30 p.m.

Yahoo · Oct 16, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass., October 16, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Com

Yahoo · Oct 12, 2026

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

BEDFORD, Mass., October 12, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 represents a novel approach to Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder, by targeting

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By